Eclipse Bioinnovations, Inc. (Eclipsebio), the leader in sequencing-based analytics and AI-enabled design for RNA therapeutics, today announced the launch of eSENSE Break™, a sequencing-based technology that maps RNA fragmentation and circular RNA nicking sites at single-nucleotide resolution.

Standard RNA integrity assays provide low resolution assessments of RNA integrity but cannot identify which nucleotide positions are undergoing fragmentation. eSENSE Break uses next-generation sequencing to generate a positional map of fragmentation sites across the full RNA sequence, showing therapeutic developers exactly where breaks are occurring.

“Fragmentation is a well-known problem in RNA therapeutic development, but it has been challenging to resolve without knowing exactly where and why breaks are occurring,” said Eclipsebio Co-Founder and CEO Peter Chu, Ph.D. “eSENSE Break gives our partners a positional view of where their RNA is breaking so they can diagnose and act on it.”

eSENSE Break is a part of Eclipsebio’s eCOMPASS™, the company’s end-to-end platform for RNA therapeutic development, and eMERGE™, the company’s sequencing-based analytics suite for RNA characterization. Paired with eSHAPE™ structure profiling, eSENSE Break also enables developers to correlate fragmentation patterns with RNA secondary structure.

Source – PR Newswire